With Revenues Down 27 Percent in 2007, Epigenomics Banks on Cancer Screening | GenomeWeb
In the coming years Epigenomics will focus on licensing its biomarker discoveries to diagnostic partners in order to develop and commercialize assays, most readily in the area of cancer screening.
 
“To maximize diagnostic platform access and ultimately market penetration and value for Epigenomics, the company moved towards a nonexclusive licensing approach in early 2007,” CEO Geert Walther Nygaard said during a conference call announcing its earnings for the 12 months ended Dec. 31, 2007.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.